Tetsuo Yamagata

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

Joe Bentz, Michael O′Connor, Dallas Bednarczyk et al. · Drug Metabolism and Disposition · 2013 · 150 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +9

Mucosal insulin delivery systems based on complexation polymer hydrogels: effect of particle size on insulin enteral absorption

Mariko Morishita, Takahiro Goto, Nicholas A. Peppas et al. · Journal of Controlled Release · 2004 · 137 citations

Pharmacy, Molecular Pharmaceutics, Pharmaceutics +17

Effect of excipients on breast cancer resistance protein substrate uptake activity

Tetsuo Yamagata, Hiroyuki Kusuhara, Mariko Morishita et al. · Journal of Controlled Release · 2007 · 107 citations

Medicine, Biochemistry, Oncology +10

Improvement of the Oral Drug Absorption of Topotecan through the Inhibition of Intestinal Xenobiotic Efflux Transporter, Breast Cancer Resistance Protein, by Excipients

Tetsuo Yamagata, Hiroyuki Kusuhara, Mariko Morishita et al. · Drug Metabolism and Disposition · 2007 · 104 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Characterization of insulin protection properties of complexation hydrogels in gastric and intestinal enzyme fluids

Tetsuo Yamagata, Mariko Morishita, Nikhil J. Kavimandan et al. · Journal of Controlled Release · 2006 · 94 citations

Natural Sciences, Biochemistry, Biomedical Engineering +16